Using a closure analysis method to reduce CGT contamination risks
Many cell therapy manufacturing processes use open unit manipulations. As a result, they are at risk of potential contam...
Using a closure analysis method to reduce CGT contamination risks
Many cell therapy manufacturing processes use open unit manipulations. As a result, they are at risk of potential contamination that can result in manufacturing batch failure. The processes therefore rely on end-to-end a...
How to replenish working cell banks with a risk-based scientific approach
Cell banks represent the fundamental starting substrates for biological drug substance/drug substance intermediate manuf...
BioPhorum’s Deliverables Report 2021 – all of our content at your fingertips
Where can you read about industry trends, progress against shared challenges, and best practice solutions...
Harmonizing the industry and improving confidence through risk-based microbial testing
LONG READHarmonizing the industry and improving confidence through risk-based microbial testingThe integrity of...
With net zero the ultimate target, how can the industry work together to usher in a sustainable future?
As the 26th UN Climate Change conference takes place in Glasgow, what part is BioPhorum playing to help the industry ach...
The Spontaneous Infection: Did you leave the back door to your cultivation suite open?
In Shared clean-in-place systems: To share or not to share? and How much harm can a single droplet do? Consideratio...
Steps to eradicate undetected contaminations in anaerobic testing
All biopharmaceutical manufacturers have a legal obligation to monitor the microorganisms that are found ...
How to appropriately classify your cleanroom at early-stage design
BioPhorum Drug Substance Closed Systems in Controlled Non-Classified Workstream has recently published its room...
The Russian Pharmacopeia: a reflection on the challenges to achieving greater alignment for biologics
The Russian Pharmacopeia: a reflection on the challenges to achieving greater alignment for biologics The Ru...
Supplier change notifications – bringing color to a grey area
Regulators require the biopharmaceutical industry to manage changes to raw materials in a compliant way – including th...
BioPhorum launch new sustainability phorum
BioPhorum members have given us a clear message; to be an industry that supports sustainability is extremely important t...
A guide to integrating CPV reporting and APR practices
Continued process verification (CPV) and annual product review (APR) practices are crucial for maintaining a state of co...
Chain reaction: how the biopharmaceutical supply chain survived the pandemic
LONG READChain reaction: how the biopharmaceutical supply chain survived the pandemicThe pressure on the...
Using a closure analysis method to reduce CGT contamination risks
Many cell therapy manufacturing processes use open unit manipulations. As a result, they are at risk of potential contam...
How to replenish working cell banks with a risk-based scientific approach
Cell banks represent the fundamental starting substrates for biological drug substance/drug substance intermediate manuf...
BioPhorum’s Deliverables Report 2021 – all of our content at your fingertips
Where can you read about industry trends, progress against shared challenges, and best practice solutions...
Harmonizing the industry and improving confidence through risk-based microbial testing
LONG READHarmonizing the industry and improving confidence through risk-based microbial testingThe integrity of...
With net zero the ultimate target, how can the industry work together to usher in a sustainable future?
As the 26th UN Climate Change conference takes place in Glasgow, what part is BioPhorum playing to help the industry ach...
The Spontaneous Infection: Did you leave the back door to your cultivation suite open?
In Shared clean-in-place systems: To share or not to share? and How much harm can a single droplet do? Consideratio...
Steps to eradicate undetected contaminations in anaerobic testing
All biopharmaceutical manufacturers have a legal obligation to monitor the microorganisms that are found ...
How to appropriately classify your cleanroom at early-stage design
BioPhorum Drug Substance Closed Systems in Controlled Non-Classified Workstream has recently published its room...
The Russian Pharmacopeia: a reflection on the challenges to achieving greater alignment for biologics
The Russian Pharmacopeia: a reflection on the challenges to achieving greater alignment for biologics The Ru...
Supplier change notifications – bringing color to a grey area
Regulators require the biopharmaceutical industry to manage changes to raw materials in a compliant way – including th...
BioPhorum launch new sustainability phorum
BioPhorum members have given us a clear message; to be an industry that supports sustainability is extremely important t...
A guide to integrating CPV reporting and APR practices
Continued process verification (CPV) and annual product review (APR) practices are crucial for maintaining a state of co...